Determination of Regulatory Review Period for Purposes of Patent Extension; ONGENTYS

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for ONGENTYS, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO), Department of Commerce. The FDA is publishing this notice as required by law.